Another French connection: Valneva SE who we have a manufacturing agreement with is French also. Lyon to be exact. Maybe hariatt got sick of the rejection over here and is gonna go the European route to approval
I hear your optimism. I see you way more excited than just a newer forum to share her technology with some well educated skeptics in the HIV old boys club.
The " Panatelo WAS the Salesman she NEEDED" sounds like something is past tense... I do not know how mergers are announced in the Bio tech world. Would it make sence for Sanofi to have a deal with Geovax and not put out a PR until the day of presentation, and then let harriatt deliver her presentation in forum before p5 to validate their rational to shareholders why they Did the DEAL ???
I do like your other points also. Why Robinson? WHY NOW??? They have known of her for years.
Hope your on to something. :)
I sent an email to your yahoo acct with the name of the board. johnheps@yahoodotcom
I am with you. Maybe there will even be some additional (UPDATE) information that was not available when she did the webcast . after all she will be opening up the discussion with an update.
but was hoping for the " we announce NIH has advanced us the $3 MILLION
for Production leading into our planned phase 2B trial scheduled to start TOMORROW." :)
ATLANTA, GA, September 25, 2014 – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing HIV/AIDS vaccines, today announced that its Chief Scientific Officer, Harriet L. Robinson, Ph.D., will participate in a panel discussion on HIV vaccine clinical trials on October 7, 2014 at the 2014 Cent Gardes HIV Vaccine Conference in Veyrier du Lac, France. In the introduction to the discussion, Dr. Robinson will provide an update on GeoVax’s HIV vaccine trials, “Clade B VLP expressing DNA/MVA Vaccine”.
The 2014 Cent Gardes HIV Vaccine Conference (October 5-7, 2014) will be devoted to the discussion of the most promising vaccine prospects for the future, and will be attended by global experts and thought leaders in HIV vaccine research and support. Among other things, the goal of the conference is to allow high-level exchanges within the scientific community, foster comparisons between various vaccine models and strategies, create collaborative approaches and help promising approaches move forward. The conference is sponsored by Foundation Merieux.
Ditto... on the auto... I have read of one individual who I think got in on the private placement , that could of bought a house, so I guess it could of been worse. ( I was in dauphin in 2001 and I think the merger happened way before their stated time of 2006, but it has been so long , time has took its toll on my memory)
Another thing that frustrates me is their projected timelines. I bought into this latest again, ( hopefully I wont be disappointed) it being ( we should hear by end of sept if NIH will advance the 3M for production of the vaccine to prepare for phase 2b trial )
Was looking back at some annual s and 8k's the other day and saw " we expect to start phase 2B in sometime in 2014. That was in 2012. there have been more than a few mistaken timelines they have put in writing.
No matter what, I guess we should never ask McNally and Co " What time is it?"
On thinking about it , I doubt it relates to Claude C. That is Africa and maybe Asia that is infected with C. I cant see them spending a lot of money in Nigeria, ect . where corruption would trump any patent one may have.
that would be like boy scouts enforcing a contract with the Mafia.
I think this goes with claude B. ie EUROPE...and developed world.
So they have applied for or received an additional 26 patents world wide. are they worried someone will go overseas to steal the technology and get around us patents. Or if this relates to claude C ???
either way that's what you do when you have bs technology .
I seem to rember only 19 Patents refrenced over the years. Anyone else rember if that was accurate? because fact sheet refers to other major world markets, now.
Strong Patent Position
HIV Immunotherapy Program - Clinical Status
Preventive HIV Vaccine - Clinical Status
GeoVax is the exclusive, worldwide licensee of 45 patents issued or filed on various components and compositions of our HIV/AIDS
vaccines. These are owned or licensed by Emory University.
7 issued and 6 filed US patents
32 issued or filed patents in other major world markets
Yes Sir... Even announcement of the 3M would guarantee the rest.
I think its in the bag, because they said (if NIH does not fund 3m we will look for outside funding to produce vaccine in prep for trial) still NIH sponcered.
This is my understanding of the statement. Do you agree ?
Would have been nice But , No, they did NOT change it. I got my quote from Clinical trials/ Preventave hiv vaccine tab on pipeline page. at bottom of page. Still the same, just using different terminology in different spots on w.s.
Phase 2b Planning
We are currently in planning discussions with the HVTN for the next stage of clinical trials for GOVX-B11. Our vaccine is currently the only vaccine being contemplated for efficacy trials for prevention of clade B HIV infection. We expect our next preventive clinical trial to begin in 2016 and to be financially supported by the NIH. Specific details of the study will be determined after further data analysis and input from the HVTN and NIH.
then 20 shares @ apx 10 am est
Total today 51 shares @ 11:30 est
same on Friday until I got the 9300 that ( to my surprise came up as NOT shorted) I think it was 80 shares total , prior to my purchase.
then 1k or so to close day.
No one can sell,transfer or trade escrow shares. Large HF or small retail holders. Everyone has to play by the same rules here. Pretty refreshing if you think about it... :)
The "immune space template" proposed here provides a standardized approach by which the quality, level, and durability of immune responses elicited in early human trials by a candidate vaccine can be described. The immune response profile will demonstrate if and how the candidate is unique relative to other candidates, especially those that have preceded it into efficacy testing and, thus, what new information concerning potential immune correlates could be learned from an efficacy trial.
Preceeded into efficacy testing, Harriatt is the only ONE in efficacy testing :)
looks like the mm doing the shorting was indeed on vacation or sick last week.
Aug 25 54.62% NA NA NA 12,900 23,617
Aug 22 0% 0.23 0.23 0.23 0 0
Aug 21 0% 0.24 0.23 0.23 0 23,000
Aug 20 3.40% 0.24 0.23 0.24 700 20,608
Aug 19 0% 0.24 0.23 0.24 0 2,200
Aug 18 95.94% 0.24 0.23 0.24 20,000 20,846